decisionhealth Newsletters, Part B News - 2000 Issue 9 (September)
Verteporfin now covered separately, HCFA announces
Subscribe or sign in to view the full article.
Article Overview
This premium article reviews an HCFA program memo on how certain ophthalmic services and related supplies were being handled for reimbursement at the time. It is relevant to coders, billing staff, and compliance teams working with ophthalmology claims, HCPCS/CPT coding, and carrier-determined coverage issues. The article focuses on the agency’s coverage and payment guidance, including how to report the service and how associated components were to be treated under the memo.
Why This Topic Matters
Readers need this guidance to understand how HCFA was distinguishing covered products from bundled procedure components and to recognize which ophthalmic services were left to carrier-level determination. The article helps situate billing and reimbursement decisions within the agency’s memo for the specified date of service period.
What You Will Learn
- How HCFA addressed reimbursement for a specific ophthalmic drug product
- How related ophthalmic procedures were being categorized for billing purposes
- What the memo said about national coverage versus carrier-determined coverage
- How the article frames the relationship between a drug product and associated procedure billing
Who Should Read This
- Medical coders
- Ophthalmology billing staff
- Revenue cycle specialists
- Compliance professionals
- Practice administrators
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com